The Natural Product Avrainvillamide Binds to the Oncoprotein Nucleophosmin
- 25 October 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 129 (46), 14444-14451
- https://doi.org/10.1021/ja075327f
Abstract
Here we present evidence that (+)-avrainvillamide, a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Among other effects, nucleophosmin is known to regulate the tumor suppressor protein p53. A synthetic biotin−avrainvillamide conjugate, nearly equipotent to the natural product in inhibiting the growth of cultured T-47D cells, was used for affinity-isolation of a protein identified as nucleophosmin by MS sequencing and Western-blotting. Affinity-isolation of nucleophosmin was inhibited in the presence of iodoacetamide (10 mM), free (+)-avrainvillamide (100 μM), and a series of closely related structural analogues of (+)-avrainvillamide, the latter with inhibitory effects that appear to correlate with measured growth-inhibitory potencies. Using fluorescence microscopy, a synthetic dansyl−avrainvillamide conjugate was observed to localize within the nucleoli and the cytosol of treated cancer cells. Site-directed mutagenesis of each of the three cysteine residues of a truncated nucleophosmin coexpressed with native nucleophosmin in COS-7 cells revealed that the mutation cys275 → ala275 effectively and uniquely reduced affinity-isolation of the truncated protein, suggesting that avrainvillamide targets cys275 of nucleophosmin. Finally, we show that treatment of adhered LNCaP or T-47D cells with (+)-avrainvillamide leads to an increase in cellular p53 concentrations, and that siRNA-promoted depletion of nucleophosmin in a population of HeLa S3 cells leads to increased sensitivity of that population toward apoptotic death upon treatment with (+)-avrainvillamide. Although potentially desirable as lead compounds for the development of novel anticancer therapies, nonpeptidic, synthetic small molecules that bind to nucleophosmin have not been described, prior to this report.Keywords
This publication has 27 references indexed in Scilit:
- Evidence for the Rapid Conversion of Stephacidin B into the Electrophilic Monomer Avrainvillamide in Cell CultureJournal of the American Chemical Society, 2007
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Nucleophosmin/B23-binding peptide inhibits tumor growth and up-regulates transcriptional activity of p53Biochemical and Biophysical Research Communications, 2005
- What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?Leukemia, 2005
- Enantioselective Synthesis of Stephacidin BJournal of the American Chemical Society, 2005
- Identification of a Novel Michael Acceptor Group for the Reversible Addition of Oxygen- and Sulfur-Based Nucleophiles. Synthesis and Reactivity of the 3-Alkylidene-3H-indole 1-Oxide Function of AvrainvillamideJournal of the American Chemical Society, 2003
- Mapping the Functional Domains of Nucleolar Protein B23Journal of Biological Chemistry, 2000
- Sedimentation Analyses of the Salt- and Divalent Metal Ion-Induced Oligomerization of Nucleolar Protein B23Biochemistry, 1996
- Interaction of nucleolar protein B23 with peptides related to nuclear localization signals and its modulation by phosphorylationBiochemistry, 1995
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976